WW INTERNATIONAL, INC. 8K

WW International, Inc. reported Q1 2026 results showing strong growth in its GLP‑1‑focused Clinical business, weaker Behavioral revenue, reaffirmed full-year 2026 revenue and adjusted EBITDA guidance, and announced a Q2 term-loan paydown funded from cash as part of its post‑reorganization transformation strategy.

WW International, Inc. (Weight Watchers) furnished a business update and shareholder letter reporting first quarter 2026 results and outlook, highlighting a 32% year-over-year increase in Clinical Subscription Revenue and a 46% increase in end-of-period clinical subscribers despite lapping prior-year compounded semaglutide growth, while Behavioral revenue declined 10% amid secular headwinds but showed growth in higher-value Core+ subscribers. The company reported Q1 2026 revenue of approximately $168 million, gross margin of 70.5% (73.6% adjusted), a net loss of $52.0 million, and an adjusted EBITDA loss of $1.8 million driven mainly by front-loaded Med+ marketing tied to GLP‑1 offerings such as Wegovy and new oral formulations. Management reaffirmed full-year 2026 guidance for revenue of $620–$635 million and adjusted EBITDA of $105–$115 million, expects positive cash generation for 2026, and plans in Q2 to use $37 million of cash (from an annual cash sweep and a voluntary solicitation at 68.5% of par) to repay $42 million of term loan principal, which should reduce annual interest expense by about $4 million. The update emphasizes an integrated weight health platform combining behavioral programs and GLP‑1-based clinical care, describes the impact of the company’s 2025 Chapter 11 financial reorganization and fresh start accounting on comparability, and outlines continued cost discipline, capital allocation priorities, and strategic focus on scaling Clinical and Core+ while stabilizing the legacy Behavioral business.

Filing Facts

CIK

105319

Ticker

-

Form

8K

Source Type

fda

Accession

0001193125-26-210279

Alert Tier

7